Skip to main content
    P

    Pfizer Inc (PFE)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE

    $28.88
    -0.01 (-0.03%)

    Market Cap: $164.67B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Pfizer Inc (PFE) P/E Ratio & Valuation History

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Pfizer (PFE) trades at 9.5x trailing earnings and 2.6x sales. Its P/E of 9.5x is above its 5-year median of 8.5x. Its forward P/E is 9.7x. The median P/E across 9 similar companies is 21.4x.

    Current Multiples

    Its forward P/E is above its trailing P/E, which implies earnings per share about 2.1% lower over the next year. PEG is left out because the growth rate behind it, P/E divided by PEG, is under 2% a year.

    MultipleValue
    P/E (trailing)9.5x
    Forward P/E9.7x
    Price to sales2.6x
    Price to book1.8x
    EV/EBITDA21.0x
    Price to FCF14.0x
    EV/FCF19.1x
    PEGN/A
    FCF yield7.2%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/E is 24.6% below 12.6x, its P/S is 29.7% below 3.7x and its P/B is 41.9% below 3.1x.

    MultipleCurrent5-year median10-year median
    P/E9.5x8.5x12.6x
    P/S2.6x2.5x3.7x
    P/B1.8x1.8x3.1x
    Medians of month-end values through Oct 2026: 60 months (5-year) and 120 months (10-year).

    Valuation History

    Over the 10 year ends shown, its P/E ranged from 7.7x in 2025 to 15.7x in 2023. 2025 was the lowest of those years.

    Year endPriceP/EP/SP/B
    2025$24.907.7x2.3x1.6x
    2024$26.538.5x2.4x1.7x
    2023$28.7915.7x2.7x1.8x
    2022$51.247.8x2.9x3.1x
    2021$59.0513.4x4.1x4.4x
    2020$36.8113.5x4.9x3.3x
    2019$39.1813.3x5.3x3.5x
    2018$43.6514.6x6.3x4.0x
    2017$36.2213.7x4.1x3.1x
    2016$32.4813.6x3.8x3.4x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewFairly valued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About PFE

    What is PFE's forward P/E ratio?

    Pfizer has a forward P/E ratio of 9.7x.

    Is PFE stock overvalued?

    GNG's valuation label for PFE is Fairly valued. Its P/E of 9.5x compares with a median of 21.4x across 9 similar companies.

    What is PFE's price to sales ratio?

    Pfizer has a price to sales ratio of 2.6x.

    What is Pfizer's average P/E ratio over 5 years?

    Pfizer's median P/E over the last 5 years is 8.5x, from 60 month-end values through Oct 2026.